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ABSTRACT (233 words) 
Purpose: PDGFRA D842V mutated GISTs are known for their insensitivity to imatinib. 
However, in clinical practice responses have been observed in some patients. We describe the 
natural history and treatment outcomes in a cohort of PDGFRA exon 18 mutated GIST 
patients. 
Patients and methods: A retrospective cohort study was conducted in PDGFRA exon 18 
mutation GIST patients treated in 6 expert centers in the Netherlands and the United States. 
Two independent radiologists assessed radiological response to imatinib according to Choi’s 
criteria in all patients with measurable disease treated with imatinib in neo-adjuvant or 
palliative intent.  
Results: Seventy-one patients with PDGFRA exon 18 mutation were identified of whom 48 
patients (69%) had a D842V mutation. Twenty-two (45.8%) D842V-mutated GIST patients 
received imatinib treatment, 16 had measurable disease. Fourteen out of  the 23(60.9%) 
patients with non-D842V mutations received imatinib treatment, 8 had measurable disease. 
Two out of 16 (12.5%) D842V-mutated GIST patients had partial response, 3 patients 
(18.8%) had stable disease and 9 patients (56.3%) had progressive disease as best response. 
Two patients did not have follow-up CT scans to assess response. Six out of 8 (75%) patients 
with non-D842V exon 18 mutations had partial response and 2 (25%) had stable disease  as 
best response.  
Conclusion:  Patients with D842V-mutated GISTs can occasionally respond to imatinib. In 
the absence of better therapeutic options, imatinib should therefore not be universally 
withheld in patients with this mutation. 
 
Keywords: Gastrointestinal stromal tumor; GIST; PDGFRA exon 18; D842V; Imatinib 
 
INTRODUCTION 
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the 
gastrointestinal tract. Important to their tumorogenesis is an activating mutation involving a 
gene, which encodes for a tyrosine kinase receptor (TKR). Most commonly, this TKR is KIT 
(~75%) and in 10% of patients, platelet-derived growth factor receptor alpha (PDGFRA). 
Approximately 15% of all GISTs are wild type for PDGFRA and KIT.[1]  
Systemic treatment with imatinib, an oral tyrosine kinase inhibitor (TKI), has been proven 
effective for a majority of patients with advanced  GIST, showing response in up to 85% of 
advanced GIST patients.[2] In addition, patients with an operable GIST with a high risk of 
recurrence can improve their progression free survival (PFS) with adjuvant imatinib. For 
these patients, adjuvant treatment with imatinib for 36 months increased PFS from 36% to 
65.6%.[3], [4] However, the affinity of TKIs depends on the type of mutation. The most 
common PDGFRA mutation, a D842V substitution in exon 18, shows primary resistance to 
imatinib in in vitro and in vivo studies.[5]–[7] Although D842V-mutated GISTs comprise a 
large majority of PDGFRA exon 18 GISTs, other mutations in exon 18 differ in their 
sensitivity to imatinib. It is therefore important to distinguish between resistant and sensitive 
mutations. However, few non-D842V GISTs have been described.  [5], [6], [8]  
According to the international guidelines, adjuvant treatment is not recommended for patients 
with D842V-mutated GIST.[9] However, there are no specific recommendations on treatment 
of these GIST patients with advanced disease.[9], [10] Despite expected resistance to 
imatinib, some advanced D842V-mutated GIST patients end up receiving imatinib either 
because of an unknown mutation status at the time of treatment or due to the absence of better 
therapeutic options. In our daily practice we noted some D842V-mutated GIST patients who 
appeared to respond to imatinib treatment. Based on these anecdotal findings we conducted an 
observational study including data from six expert centers in the Netherlands and the United 
States. We describe treatment and responses in all GISTs harboring a mutation in PDGFRA 




Three cohorts of patients were defined: 1)  patients included in the Dutch GIST Registry 
(DGR); 2) patients with a PDGFRA exon 18 mutation identified from the pathology database 
of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AvL) in 
Amsterdam, Netherlands; and 3)  patients with a PDGFRA exon 18 mutation identified from 
the pathology database of the MD Anderson Cancer Center (MDACC), Houston, USA. 
The DGR includes all GIST patients diagnosed with GIST between January 2009 and March 
2015 in the 5 GIST centers in the Netherlands: the NKI-AvL, Leiden University Medical 
Centre, Erasmus University Medical Centre, Radboud University Nijmegen Medical Centre 
and the University Medical Center Groningen.  
Within the pathology database of the NKI-AvL all GIST patients diagnosed before January 
2009 with PDGFRA exon 18 mutations were identified. Patients identified from the pathology 
databases were included in the analyses when a medical record was available. Data 
acquisition was approved by the local independent ethics committees, and the study was 
conducted in accordance with the Declaration of Helsinki. 
 
Clinical data selection 
The DGR contains demographic and clinical variables, including age, gender, relevant family 
history, and primary tumor location, size, and stage. Furthermore, pathology reports 
describing histology, immunohistochemistry, and mutational status are entered in the 
database. Local and systemic therapies and all hospital visits were registered, including 
computed tomography (CT) scans and magnetic resonance imaging (MRI). For patients who 
were not entered in the DGR, clinical data points were collected using medical records.   
 
Molecular diagnosis  
For MDACC patients, PCR based DNA sequencing for KIT  and PDGFRA was performed at 
the Molecular Diagnostics Laboratory at the University of Texas MDACC. Formalin fixed 
paraffin embedded blocks with tumor were selected and 4 um-thick sections prepared. 
Genomic DNA samples were isolated from micro-dissected paraffin-embedded slides using a 
QIAamp DNA minikit (Qiagen, Germantown, MD, USA). For PCR, primer sets for exons 9. 
11, 13, and 17 of the KIT gene and for exon 18 of the PDGFR gene were used.  PCR was 
carried out in a total volume of 25 μl containing 50–100 ng of genomic DNA and 0.25 uL of 
DNA polymerase (Bioline, London, UK). Mutations were identified by sequencing the PCR 
products on a 3730×1 DNA analyzer (Applied Biosystems, Carlsbad, CA, USA).  
 
For most Dutch sites, routine mutation analysis included analysis of KIT (exons 9, 11, 13 and 
17) and PDGFRA (exons 12, 14 and 18) by Sanger Sequencing. 5-10um FFPE sections of 
tumor material were used for DNA isolation using standard procedures (KAPA Express 
Extract Kit, Kapa Biosystems, Massachusetts, USA). An area for micro-dissection of tumor 
cells was indicated by a pathologist. Sequencing was performed on a capillary sequencer 
(ABI 3730 DNA Analyzer, Life Technologies, USA), mutation analysis was performed using 
specific software (MutationSurveyer, Softgenetics, USA). 
 
For validation purposes, repeated molecular analyses were performed in samples from 
multiple sites of the resected tumors for all patients with a D842V-mutated GIST with partial 
response (PR).  
Radiological response evaluation 
In all patients with measurable disease treated in neo-adjuvant or palliative setting 
radiological tumor measurements were re-evaluated by two independent radiologists using 
Choi’s criteria: partial response (PR) was defined as at least 10% decrease in maximal 
diameter as measured according to Response Evaluation Criteria in Solid Tumors (RECIST) 
or 15% decrease or more in hounsfield units (HU); progressive disease (PD) was determined 
in case of an increase in tumor diameter of 10% and if the tumor does not meet the PR criteria 
by tumor attenuation on CT; if the tumor did not meet either of the criteria for PR or PD, 
response was defined as stable disease (SD).[11] If the outcomes of both radiologists did not 
correspond, an outcome was determined based on consensus.  
 
Pathological response evaluation 
Histologic response evaluation was conducted in patients who received imatinib prior to 
surgery. Response was graded based on the microscopic amount of necrosis and fibrosis 
according to the following scheme, that is based on consensus between pathologists in the 
MD Anderson and the NKI-AvL: 1) minimal (<10%); 2) moderate (10-50%); and 3) good 
(>50%). Grading was done at the MDACC and in the AvL-NKI population separately.  
 
Statistical analysis 
Median time to progression (TTP) was calculated for all patients with measurable disease 
treated with neo-adjuvant or palliative intent. It was calculated from the date of initiation of 
imatinib treatment to the date of radiological or clinical progression prompting the physician 
to change treatment strategy. Statistical analysis was performed using Statistical Package for 




In the DGR, 678 GIST patients were identified of whom 42 patients with GIST harboring a 
mutation in PDGFRA exon 18. The pathology databases of the NKI-AvL and the MDACC 
revealed 29 additional PDGFRA exon 18 mutated GIST patients; 10 at the NKI-AvL and 19 
at the MDACC. In total 71 non-overlapping GIST patients were identified with a PDGFRA 
exon 18 mutation of whom 48 (69%) patients with a D842V-mutated GIST. (Figure 1) 
 
D842V-mutated GISTs 
Over 90% of patients had local or locally advanced disease at registry entry. Twenty-two 
patients received systemic treatment with imatinib out of which 17 patients were treated with 
neo-adjuvant or palliative intent. All but one had measurable disease at the start of therapy, 
since this lesion was below the detection criteria for CT evaluation. (Table 1) Two patients 
had PR. (Figure 2) Three patients had SD, and 9 patients had PD as best response. For 2 
patients no follow-up CT scans were available; one patient underwent resection shortly after 
the start of therapy and one patient had started therapy recently and was therefore not 
evaluable yet. Pathological response was evaluated in 7 out of 12 neo-adjuvant treated 
patients. None of these cases showed a good pathologic response. (Table 2). Repeated 
molecular analyses in different parts of the tumor from the two patients showing PR 
confirmed a D842V mutation in all tumor regions.  
Median follow-up time for all patients receiving imatinib with neo-adjuvant and palliative 
intent was 11 months (range 0-131). Out of 17 patients treated with neo-adjuvant and 
palliative intent, 10 patients showed PD. Median TTP was 8 months (range 0-42). Patients 
who progressed on imatinib showed a median TTP of 2.5 months (range 0-8). Five patients 
had died during follow-up, 3 due to disease progression.  
Three out of 11 patients in the high-risk category received adjuvant treatment, and no patients 
showed recurrence in this group during median follow-up period of 23 months (range 1-84). 
Out of 8 high-risk patients who did not receive adjuvant treatment two had recurrence during 
the follow-up period. 
 
Non-D842V mutated GISTs 
Seventeen patients with a non-D842V mutated GIST had local or locally advanced disease at 
registry entry. Three patients received imatinib with neo-adjuvant intent and 5 with palliative 
intent, resulting in 8 non-D842V mutated GIST patients with measurable disease. Six patients 
had PR and two patients had SD as best response. Good pathologic response was seen in one 
patient harboring a I843_D846del mutation out of two patient who had pathologic evaluation. 
Table 2 describes all specific mutations in PDGFRA exon 18 in patients with measurable 
disease and their responses. (Table 2) 
Median follow-up time for patients receiving imatinib with neo-adjuvant or palliative intent 
was 24.5 months (range 3-132). Two patients had progression; one patient progressed within 
7 months and the other patient progressed within 27 months.  
Three out of the four high-risk patients received adjuvant treatment. One had recurrence after 
one year of adjuvant imatinib therapy. Two patients, who did not receive adjuvant treatment, 




We assessed responses to imatinib in GIST patients harboring a PDGFRA exon 18 mutation 
in a large observational cohort treated in routine clinical care. Interestingly, we showed that a 
small fraction of D842V-mutated GISTs respond to treatment with imatinib. One remains 
recurrence free after neo-adjuvant treatment for almost 3 years and the other is progression 
free during the 10 years of follow-up. 
The response to imatinib in D842V-mutated GIST in our study contrasts the responses 
described in prior in vivo and in vitro studies. In these studies, D842V mutation has 
consistently shown to be imatinib-resistant.[5], [6] In one study by Cassier et al (2012), in 
vivo response was described in 32 D842V-mutated GIST’s, showing no PR, 21 patients with 
PD and the rest with SD as best response.[6] These findings are similar to those found in the 
study conducted by Corless et al in 2005.[5] They found 35 patients in their study and 181 
unique patients in total described in literature with a D842V mutation in exon 18. None of 
these patients showed response to imatinib. In these studies response evaluations were 
conducted by RECIST. It is well known that response by Choi’s criteria is correlated with 
TTP and that size-based response criteria may lead to an underestimation of the imatinib 
response in GIST.[12], [13] However, the responses in the two D842V-mutated GIST patients 
in our study would have been classified as PR even by RECIST guidelines. Though no 
additional mutations were detected in our patient samples and repeated molecular analyses 
confirmed D842V mutation, one could speculate that heterogeneity within the tumor might 
have resulted in the responses noted in our patients. [14]  
 
Similar to the earlier studies a large proportion of the D842V-mutated patients had PD as best 
response with a short TTP. This resistance to imatinib is thought to be the result of D842V 
mutation affecting the tyrosine kinase receptor activation loop. A D842V mutation in 
PDGFRA leads to reduced accessibility of the ATP pocket and thereby to relative resistance 
to imatinib.[1] Corless et al have found that other substitutions in codon 842, except for 
D842Y, also show resistance to imatinib.[5]  
 
In line with prior studies we found that patients with a non-D842V mutated GIST respond 
well to imatinib. Despite the fact that the imatinib resistant D842V mutation comprises a large 
majority of mutations in PDGFRA exon 18, approximately 30% have other mutations 
involving exon 18 of PDGFRA and all have shown favorable responses to imatinib.[5], [15], 
[16] Also, median TTP in our non-D842V mutated GIST patients with advanced disease was 
similar to other imatinib sensitive GIST patients.   
 
International guidelines regarding adjuvant and neo-adjuvant treatment do not recommend 
imatinib for GIST patients harboring a D842V mutation.[9] It is therefore important to 
perform mutation analysis to determine the driver mutation and its sensitivity to imatinib. 
Interestingly, imatinib with neo-adjuvant and adjuvant intent was still frequently given in our 
cohort of D842-mutated GIST. It is possible that the mutation results were not available at the 
time of initiation of therapy. Nine D842V-mutated GIST patients in our cohort were given 
adjuvant or neo-adjuvant treatment. Patients with PDGFRA exon 18 mutated GIST often have 
low mitotic activity and are considered to be low risk. Joensuu et al. showed that a mitotic 
count of over 5 per 50 high power field (hpf) predicts for high risk for recurrence.[15] It is 
unknown whether with D842V-mutated GIST might benefit from adjuvant treatment. 
Although in our cohort slightly more recurrences occurred in non-treated patients with a high 
risk tumor, no conclusions can be drawn considering the low patient numbers and 
heterogeneous follow-up time.  
 
In case of a locally advanced tumor, the ESMO guideline recommends resection without prior 
imatinib therapy in less sensitive tumors like D842V-mutated GISTs. Twelve of our patients 
with locally advanced GIST received imatinib and a quarter did not undergo surgery 
eventually. Again, it is unclear if the treating physician had the mutation data available at the 
time of treatment initiation.  
 
For GIST patients harboring a D842V mutation with advanced disease no specific 
recommendations on treatment are described in international guidelines.[9], [10] Given the 
known resistance to imatinib in D842V-mutated GIST, therapeutic alternatives are being 
investigated but proven therapies are still lacking.[17]–[20] Therefore, it was not a surprise to 
us that imatinib is still given in routine clinical care and this helped us evaluate the utility of 
imatinib in this population.  
 
Patients in our study were treated in 6 different expert centers, resulting in a representative 
sample of patients. Evaluation of best response was confirmed by two independent 
radiologists according to Choi’s criteria. No prior study has described in vivo pathologic 
response in PDGFRA exon 18 patients. Agaram et al show little to no correlation between 
radiological and pathological response in GIST patients.[21] There is however evidence that 
patients with good pathological response show better PFS and overall survival (OS).[22] In 
our cohort only one patient with good radiological response to imatinib had good pathologic 
response. Further interpretation is limited due to small numbers. 
 
Even though our sample size is small, considering the rarity of PDGFRA exon 18 mutated 
GISTs, this is the first and largest cohort to date of patients treated in routine clinical care 
described in the literature. Unlike what has previously been described we have found clinical 
and radiological responses in few patients with D842V-mutated GIST. Considering that GIST 
might be a multiclonal disease, one might argue that these patients could have had different 
clones within their tumours. Therefore, in our view imatinib treatment should not be 
universally denied in D842V-mutated GISTs who are not surgically resectable.  Given the 
lack of alternative treatments in advanced disease, it may be worthwhile to start imatinib 
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Fig 2. Radiological response in a neo-adjuvant treated D842V-mutated GIST patient 

















Table 2. Radiological Choi responses and pathological responses in patients with 
measurable disease treated with palliative or neo-adjuvant intent. 
 
 
 
 
 
 
 
 
 
 
 
 
